WO2003010336A3 - Molekulare marker beim hepatozellulären karzinom - Google Patents

Molekulare marker beim hepatozellulären karzinom Download PDF

Info

Publication number
WO2003010336A3
WO2003010336A3 PCT/EP2002/008305 EP0208305W WO03010336A3 WO 2003010336 A3 WO2003010336 A3 WO 2003010336A3 EP 0208305 W EP0208305 W EP 0208305W WO 03010336 A3 WO03010336 A3 WO 03010336A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcc
relates
molecular markers
hepatocellular carcinoma
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/008305
Other languages
English (en)
French (fr)
Other versions
WO2003010336A2 (de
Inventor
Sabine Debuschewitz
Juergen Jobst
Stephan Kaiser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP02790191A priority Critical patent/EP1507871A2/de
Publication of WO2003010336A2 publication Critical patent/WO2003010336A2/de
Priority to PCT/EP2003/008243 priority patent/WO2004011945A2/de
Priority to AU2003253329A priority patent/AU2003253329A1/en
Priority to EP03771105A priority patent/EP1525477A2/de
Anticipated expiration legal-status Critical
Publication of WO2003010336A3 publication Critical patent/WO2003010336A3/de
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Die vorliegende Erfindung betrifft molekulare Marker, die beim hepatozellulären Karzinom auftreten. Sie umfasst insbesondere Gensequenzen bzw. davon codierte Peptide, die beim Leberzellkarzinom (HCC) gegenüber gesunden, normalen Leberzellen in der Expression herauf- oder herabreguliert sind, sowie die Verwendung dieser Sequenzen zur Diagnose oder/und Therapie von HCC sowie zum Screening zur Identifizierung neuer Wirkstoffe für HCC. Weiterhin betrifft die Erfindung ein HCC-spezifisches Cluster als einzigartiges diagnostisches Mittel für HCC.
PCT/EP2002/008305 2001-07-25 2002-07-25 Molekulare marker beim hepatozellulären karzinom Ceased WO2003010336A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP02790191A EP1507871A2 (de) 2001-07-25 2002-07-25 Molekulare marker beim hepatozellulären karzinom
PCT/EP2003/008243 WO2004011945A2 (de) 2002-07-25 2003-07-25 Molekulare marker für das cholangioläre karzinom
AU2003253329A AU2003253329A1 (en) 2002-07-25 2003-07-25 Molecular markers for cholangiolar carcinoma
EP03771105A EP1525477A2 (de) 2002-07-25 2003-07-25 Molekulare marker für das cholangioläre karzinom

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10136273.0 2001-07-25
DE2001136273 DE10136273A1 (de) 2001-07-25 2001-07-25 Molekulare Marker beim hepatozellulären Karzinom

Publications (2)

Publication Number Publication Date
WO2003010336A2 WO2003010336A2 (de) 2003-02-06
WO2003010336A3 true WO2003010336A3 (de) 2004-12-29

Family

ID=7693073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/008305 Ceased WO2003010336A2 (de) 2001-07-25 2002-07-25 Molekulare marker beim hepatozellulären karzinom

Country Status (3)

Country Link
EP (1) EP1507871A2 (de)
DE (1) DE10136273A1 (de)
WO (1) WO2003010336A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9097714B2 (en) 2009-12-16 2015-08-04 Sekisui Medical Co., Ltd. Method for diagnosing malignant tumor

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005522677A (ja) * 2002-04-08 2005-07-28 シファーゲン バイオシステムズ， インコーポレイテッド 肝細胞癌の血清バイオマーカー
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
ATE451477T1 (de) * 2003-09-05 2009-12-15 Univ Jefferson Diagnose und überwachung von hepatozellulärem karzinom
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2006009950A2 (en) * 2004-06-21 2006-01-26 Exelixis, Inc. Aldos as modifiers of the igf pathway and methods of use
US20060057670A1 (en) * 2004-09-10 2006-03-16 The Chinese University Of Hong Kong Genomic markers of hepatitis B virus associated with hepatocellular carcinomas
JP4801930B2 (ja) * 2005-05-02 2011-10-26 株式会社Ｍｃｂｉ 新規肝がんバイオマーカーおよび該バイオマーカーを用いた肝がんの検出方法
ES2324128A1 (es) * 2005-09-29 2009-07-30 Proyecto De Biomedicina Cima, S.L. Metodo para el diagnostico de carcinoma hepatocelular mediante el empleo de marcadores moleculares.
WO2007053659A2 (en) * 2005-11-01 2007-05-10 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of screening for hepatocellular carcinoma
JP2009178057A (ja) * 2008-01-29 2009-08-13 Miyazakiken Sangyo Shien Zaidan インターフェロンとリバビリンとの併用治療効果の検出方法および検出キット
EP2269071B1 (de) 2008-03-19 2014-10-01 China Synthetic Rubber Corporation Verfahren und wirkstoffe zur diagnose und behandlung eines leberzellenkarzinoms
CA2720563A1 (en) * 2008-04-11 2009-10-15 China Synthetic Rubber Corporation Methods, agents and kits for the detection of cancer
EP2138589A1 (de) * 2008-06-27 2009-12-30 Institut Pasteur Molekulare Signatur des Lebertumorgrades und Verwendung zur Bewertung der Prognose und therapeutischen Durchführung
WO2009156858A1 (en) * 2008-06-27 2009-12-30 Institut Pasteur Molecular signature of liver tumor grade and use to evaluate prognosis and therapeutic regimen
EP2346904B1 (de) 2008-10-29 2017-04-12 China Synthetic Rubber Corporation Methoden und mittel zur diagnose und behandlung von hepatozellulärem karzinom
WO2010151731A1 (en) * 2009-06-26 2010-12-29 University Of Utah Research Foundation Materials and methods for the identification of drug-resistant cancers and treatment of same
ES2354922B1 (es) 2009-09-02 2012-02-07 Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
US9493552B2 (en) 2013-11-15 2016-11-15 China Synthetic Rubber Corporation Therapeutic biologic for treatment of hepatocellular carcinoma
MX357018B (es) * 2013-12-18 2018-06-05 Instituto Nac De Medicina Genomica Método de diagnóstico temprano de carcinoma hepatocelular.
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAWAI HIROSHI F ET AL: "alpha-Fetoprotein-producing hepatoma cell lines share common expression profiles of genes in various categories demonstrated by cDNA microarray analysis.", HEPATOLOGY, vol. 33, no. 3, March 2001 (2001-03-01), pages 676 - 691, XP009018388, ISSN: 0270-9139 *
OHMACHI YOSHITAKA ET AL: "Expression of the pancreatic secretory trypsin inhibitor gene in the liver infected with hepatitis B virus.", JOURNAL OF HEPATOLOGY, vol. 21, no. 6, 1994, pages 1012 - 1016, XP009018381, ISSN: 0168-8278 *
OHMACHI YOSHITAKA ET AL: "Specific expression of the pancreatic-secretory-trypsin-inhibitor (PSTI) gene in hepatocellular carcinoma.", INTERNATIONAL JOURNAL OF CANCER, vol. 55, no. 5, 1993, pages 728 - 734, XP009018365, ISSN: 0020-7136 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9097714B2 (en) 2009-12-16 2015-08-04 Sekisui Medical Co., Ltd. Method for diagnosing malignant tumor

Also Published As

Publication number Publication date
EP1507871A2 (de) 2005-02-23
WO2003010336A2 (de) 2003-02-06
DE10136273A1 (de) 2003-02-13

Similar Documents

Publication Publication Date Title
WO2003010336A3 (de) Molekulare marker beim hepatozellulären karzinom
WO2008057459A3 (en) Antagonists of pcsk9
WO2008057457A3 (en) Antagonists of pcsk9
WO2008133647A3 (en) Antagonists of pcsk9
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2002026944A3 (en) METHODS AND COMPOSITIONS EMPLOYING A NOVEL STEAROYL-CoA DESATURASE-hSCD5
WO1999054461A3 (de) Menschliche nukleinsäuresequenzen aus endometriumtumorgewebe
WO2001092308A3 (en) Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
MXPA02012743A (es) Moleculas tipo il-17 y usos de las mismas.
WO2005113592A3 (en) Interferon-alpha polypeptides and conjugates
WO2001070977A3 (en) Fibroblast growth factor receptor-like molecules and uses thereof
WO2004046365A3 (en) Interferon-alpha polypeptides and conjugates
AU2002338852A1 (en) Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
WO2001068854A3 (en) Fibroblast growth factor-like molecules and uses thereof
WO2003016563A3 (fr) Cible moleculaire de la neurotoxicite
WO1999054460A3 (de) Menschliche nukleinsäuresequenzen aus normalem blasengewebe
WO1999054353A3 (de) Menschliche nukleinsäuresequenzen aus uterusnormalgewebe
AU5305000A (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2003076610A3 (fr) Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations
EP1218392A4 (de) Gene die proteine kodieren welche prognostische, diagnostische, präventive, therapeutische und andere verwendungen besitzen
WO2005022164A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 8 (klk8)
WO2004031365A3 (en) Sulfatases and methods of use thereof
WO2000061196A3 (en) Fatty acid analogs for diagnosis of coronary artery disease
WO2004011945A3 (de) Molekulare marker für das cholangioläre karzinom
WO2001011039A3 (de) Sequenzvarianten des menschlichen 1-adrenozeptorgens und ihre verwendung

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG US

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002790191

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002790191

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002790191

Country of ref document: EP